Understanding adherence to neuroleptic treatment in schizophrenia

被引：29

作者：

Vauth, R

Löschmann, C

Rüsch, N

Corrigan, PW

机构：

[1] Univ Basel Hosp, Dept Psychiat Outpatient Treatment, Psychiat Univ Poliklin, CH-4005 Basel, Switzerland

[2] Univ Freiburg, Dept Psychiat, Freiburg, Germany

[3] Univ Freiburg, Dept Psychol, Freiburg, Germany

[4] Univ Chicago, Ctr Psychiat Rehabil, Chicago, IL 60637 USA

来源：

PSYCHIATRY RESEARCH | 2004年 / 126卷 / 01期

关键词：

schizophrenia; compliance; treatment adherence; shared treatment decision making; predictive value of tests;

D O I：

10.1016/j.psychres.2003.07.004

中图分类号：

R749 [精神病学];

学科分类号：

100205 ;

摘要：

Understanding the factors that impede and promote adherence by people with schizophrenia to neuroleptic medication is important for treatment planning and relapse prevention. A total of 184 DSM-IV schizophrenia inpatients were examined with the Rating of Medication Influences (ROMI) scale within a context of inpatient vocational rehabilitation. Confirmatory factor analysis was used to evaluate the underlying dimensions of compliance behavior. The three-dimensional model of Weiden and his associates was confirmed by this study; specific factors included influence of others, medication affinity, and prevention. Additional analyses examined cognitive variables, symptoms, and Course variables as predictors of individual factors. Verbal memory and cognitive flexibility were found to be associated with influence of others. Possible consequences for designing compliance enhancing therapeutic interventions are discussed. (C) 2004 Elsevier Ireland Ltd. All rights reserved.

引用

页码：43 / 49

页数：7

共 43 条

[1]

[Anonymous], 1996, User Guide for the Structural Clinical Interview for DSM-IV Axis I Disorders

[2]

[Anonymous], 1984, WMS-R: Wechsler Memory Scale-Revised: Manual

[3]

Aquila R, 1999, J CLIN PSYCHIAT, V60, P23

[4] CLINICAL SYMPTOMATOLOGY AND DRUG COMPLIANCE IN SCHIZOPHRENIC-PATIENTS [J].